Antiangiogenic therapy for cancer: current and emerging concepts.
about
Modes of resistance to anti-angiogenic therapyTargeted anti-vascular therapies for ovarian cancer: current evidenceIntertwined regulation of angiogenesis and immunity by myeloid cellsThe role of lymphatics in cancer as assessed by near-infrared fluorescence imagingMural cell associated VEGF is required for organotypic vessel formationVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.Three-dimensional imaging of xenograft tumors using optical computed and emission tomography.Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based MedicineCombination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy.Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancerPhase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Continuous sensing of tumor-targeted molecular probes with a vertical cavity surface emitting laser-based biosensor.Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.Primed infusion with delayed equilibrium of Gd.DTPA for enhanced imaging of small pulmonary metastasesCurrent and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screeningIntratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer TherapyImproved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsySilver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis.Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivoScience and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.Carboplatin and bevacizumab for recurrent malignant glioma.Bevacizumab and ovarian cancerEarly perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.
P2860
Q24608005-BA346681-E796-4CDD-9392-E68873067736Q26830287-D84BB576-612E-40C5-8205-CF329AE92286Q26830418-AF43BC60-54B9-4728-A519-92BB07467D5BQ27001155-519B1E3C-C690-4B95-BD65-F2F655B890D9Q27348757-90D2258C-169C-487F-A979-EE94E19CB0DBQ30469815-7182D033-2F3D-4474-86EE-AA637550E829Q30934034-59C53C75-D9B3-4800-9CCB-DA492DC6FBBFQ33259416-9D93057E-CBE6-49BD-8B96-A7252E556A04Q33391770-90E4D0F1-36CF-4319-AE94-ACA1341F0B5DQ33424301-C33E648A-7D8B-4237-94CB-8815F57AE61EQ33572395-9BF52818-3CD5-4101-B797-68DE130D6537Q33658626-FC540BAE-7598-4010-8E27-96FB6B0752E6Q33688219-560D0C8F-7BC5-4C28-BFBD-EB385046297CQ33698791-77144E66-BBA1-426B-8270-BB44FB063DCBQ33760569-5C5FB7B8-E2C2-48A9-9944-92DDF04420C8Q33829569-43EAB6A2-BF0C-4DD7-BFB7-AA667798482CQ33858304-3159F0D2-1681-4A84-8FA4-B5C795FD3867Q33986198-D4EFAA86-4DA6-4CAB-B894-CAA73626E73BQ34129496-3978B392-AAF9-4CCC-9B50-23A4CBCFD9F4Q34143251-E454CA25-4F02-411B-B0BD-18F0FDA2F48DQ34403657-E5AB75DA-9F9C-4B34-8206-0D0EA8F27BF2Q34450520-01F0D7C4-DB69-476C-95A1-4444EE1743D5Q34466244-6895CA1B-620D-4B74-AB2F-687905287482Q34480549-89780CD5-3055-4711-A3A7-F7D35E8F539EQ34575787-0DD4444B-8F31-461C-82B8-18AB4B725F0AQ34700347-116FC66D-054E-476F-9F5A-7CFB98B7FA0BQ34757171-3B5F686C-309F-4201-9C50-CCDC93F327D2Q34971882-82F5195B-F9E9-42D8-9DB5-BF6F718F91E9Q35561003-87388EB7-6EC3-48EA-A41B-95DCFB65A282Q35599819-A42B36D6-383F-4F51-8970-8485F4C14868Q35607779-C76DCBAA-8AAF-4B7A-A35A-709086DD154FQ35670736-09D3D64B-B9FA-42B6-9650-1C504740882DQ35960407-3E7B2981-E08D-4864-904E-6958BDD66AF3Q36229000-F71B9945-AB81-4FA1-A0F3-FA71069872A2Q36287670-8E1870CE-9BC0-4AE5-B63F-99896DF01784Q36306542-25B3AB75-6043-4E26-A1DD-348461E72D70Q36394925-8813B886-F83F-4CA0-9446-B3E7FDAD2D30Q36403389-90581A61-2D3C-4FA6-ABCD-74B4392C8D34Q36567390-0B20C15D-749E-4A81-840D-77E9EB879BF8Q36641544-0F20FCAA-F55E-463D-A670-E73EC6289FD5
P2860
Antiangiogenic therapy for cancer: current and emerging concepts.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antiangiogenic therapy for cancer: current and emerging concepts.
@ast
Antiangiogenic therapy for cancer: current and emerging concepts.
@en
type
label
Antiangiogenic therapy for cancer: current and emerging concepts.
@ast
Antiangiogenic therapy for cancer: current and emerging concepts.
@en
prefLabel
Antiangiogenic therapy for cancer: current and emerging concepts.
@ast
Antiangiogenic therapy for cancer: current and emerging concepts.
@en
P1433
P1476
Antiangiogenic therapy for cancer: current and emerging concepts.
@en
P2093
Rakesh K Jain
P433
P577
2005-04-01T00:00:00Z